Search

Displaying results 7791 - 7800 of 10000 in total
  1. Drug

    NKX101

    go.drugbank.com/drugs/DB18131
    Investigational

    NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.

    Synonyms: a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15
  2. Drug

    PBKR03

    go.drugbank.com/drugs/DB18138
    Investigational

    PBKR03 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme.

  3. Drug

    TN-401

    go.drugbank.com/drugs/DB18140
    Investigational

    TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.

    Synonyms: A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene
  4. Drug

    Berbamine

    go.drugbank.com/drugs/DB18146
    Experimental

    Synonyms: D-berbamine, 6,6',7-trimethoxy-2,2'-dimethylberbaman-12-olCategories: Heterocyclic Compounds, 2-Ring
  5. Drug

    IK-930

    go.drugbank.com/drugs/DB18149
    Investigational

    IK-930 is an oral, paralog-selective TEAD inhibitor.

  6. Drug

    ENA-001

    go.drugbank.com/drugs/DB18153
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    CT103A

    go.drugbank.com/drugs/DB18180
    Investigational

    CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.

  8. Drug

    CT120

    go.drugbank.com/drugs/DB18181
    Investigational

    CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.

  9. Drug

    Efocipegtrutide

    go.drugbank.com/drugs/DB18194
    Investigational

    Efocipegtrutide is a long-acting, monomeric peptide triple agonist.

    Synonyms: IMMUNOGLOBULIN G4 (HUMAN .GAMMA.4-CHAIN C REGION C-TERMINAL FRAGMENT), DIMER, 1-(1-(3-HYDROXYPROPYL)-L-PROLINE), 1-ETHER WITH .ALPHA.-(3-((3-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOPROPYL)AMINO)PROPYL, HM15211 (LONG-ACTING GLP-1/GIP/GLUCAGON TRIPLE AGONIST)
  10. Drug

    XMT-2056

    go.drugbank.com/drugs/DB18230
    Investigational

    XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.